Boston Scientific 

€77
257
+€1+1.32% Friday 07:05

통계

낮 최고
77
낮음
77
52W 높음
77
52W 낮음
49.9
거래량
13
평균 거래량
21
시가 총액
-
주가수익률
-
배당수익률
-
배당금
-

예정

수익

23Oct예상
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
다음
0.4
0.46
0.51
0.57
예상 EPS
0.53152551352
실제 EPS
해당 없음

다른 인물도 팔로우하고 있습니다

이 목록은 Stock Events에서 1BSX.MI을(를) 팔로우하는 사람들의 워치리스트에 기반한 것입니다. 이는 투자 권유가 아닙니다.

경쟁자

이 목록은 최근 시장 이벤트에 기반한 분석입니다. 투자 권장사항이 아닙니다.

개요

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Show more...
CEO
Mr. Michael F. Mahoney
직원
41000
국가
United States
ISIN
US1011371077

목록